Literature DB >> 33271289

Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

T Powles1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33271289     DOI： 10.1016/j.annonc.2020.11.016

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

1.  Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma.

Authors:  Jin Liu; Binwen Sun; Kun Guo; Zhou Yang; Yidan Zhao; Mingwei Gao; Zeli Yin; Keqiu Jiang; Chengyong Dong; Zhenming Gao; Mingliang Ye; Jing Liu; Liming Wang
Journal:  Cancer Gene Ther       Date:  2022-07-28       Impact factor: 5.854

2.  Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.

Authors:  Stefanie D Krens; Wim van Boxtel; Maike J M Uijen; Frank G A Jansman; Ingrid M E Desar; Sasja F Mulder; Carla M L van Herpen; Nielka P van Erp
Journal:  Int J Cancer       Date:  2021-09-16       Impact factor: 7.316

Review 3.  An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives.

Authors:  Romain Iaxx; Felix Lefort; Charlotte Domblides; Alain Ravaud; Jean-Christophe Bernhard; Marine Gross-Goupil
Journal:  Ther Clin Risk Manag       Date:  2022-06-02       Impact factor: 2.755

Review 4.  Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.

Authors:  Michela Roberto; Andrea Botticelli; Martina Panebianco; Anna Maria Aschelter; Alain Gelibter; Chiara Ciccarese; Mauro Minelli; Marianna Nuti; Daniele Santini; Andrea Laghi; Silverio Tomao; Paolo Marchetti
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.

Authors:  Nizar M Tannir; Daniel C Cho; Adi Diab; Mario Sznol; Mehmet A Bilen; Arjun V Balar; Giovanni Grignani; Erika Puente; Lily Tang; David Chien; Ute Hoch; Arkopal Choudhury; Danni Yu; Sue L Currie; Mary A Tagliaferri; Jonathan Zalevsky; Arlene O Siefker-Radtke; Michael E Hurwitz
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

6.  Urologic malignancies: advances in the analysis and interpretation of clinical findings.

Authors:  Felice Crocetto; Carlo Buonerba; Vincenzo Caputo; Matteo Ferro; Francesco Persico; Francesco Trama; Ester Iliano; Sebastiano Rapisarda; Maida Bada; Gaetano Facchini; Antonio Verde; Sabino De Placido; Biagio Barone
Journal:  Future Sci OA       Date:  2021-02-04

7.  Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.

Authors:  Stefanie D Krens; Nielka P van Erp; Stefanie L Groenland; Dirk Jan A R Moes; Sasja F Mulder; Ingrid M E Desar; Tom van der Hulle; Neeltje Steeghs; Carla M L van Herpen
Journal:  BMC Cancer       Date:  2022-03-02       Impact factor: 4.430

8.  The lncRNA Signatures of Genome Instability to Predict Survival in Patients with Renal Cancer.

Authors:  Liang Huang; Yu Xie; Shusuan Jiang; Weiqing Han; Fanchang Zeng; Daoyuan Li
Journal:  J Healthc Eng       Date:  2021-12-07       Impact factor: 2.682

Review 9.  Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances.

Authors:  Miao He; Qihua He; Xiuyu Cai; Zisheng Chen; Shen Lao; Hongsheng Deng; Xiwen Liu; Yongmei Zheng; Xiaoyan Liu; Jun Liu; Zhanhong Xie; Maojin Yao; Wenhua Liang; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2021-05

Review 10.  Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.

Authors:  Ray Manneh; Mauricio Lema; Lucía Carril-Ajuria; Linda Ibatá; Susan Martínez; Daniel Castellano; Guillermo de Velasco
Journal:  Biomedicines       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.